News for CRISPR Therapeutics AG (CRSP)

Stocks Analysis by Investing.com (Chinmay Pandya) covering: Ionis Pharmaceuticals Inc, Lattice Semiconductor Corporation, Manchester United Ltd, Five Below Inc. Read Investing.com (Chinmay Pandya)'s latest article on Investing.com

CRISPR Therapeutics AG (NASDAQ:CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ETCompany ParticipantsSamarth Kulkarni -...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

On February 26, 2025, John Greene, a Director at CRISPR Therapeutics AG, purchased 7,000 shares of the company. This transaction marks the insider's total owner

Summary CRISPR Therapeutics AG (CRSP), a pioneering biopharmaceutical company specializing in gene-based medicines, announced on February 26, 2025, that its sen

ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics ( CRSP), a biopharmaceutical company focused on creating transformative gen

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts.

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. And retail traders should know. We noticed this today when the...

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

On December 31, 2024, Catherine Wood (Trades, Portfolio), a prominent figure in the investment world, executed a strategic transaction involving CRISPR Therapeu

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's s...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more here.

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?